Share This Page
Drug Price Trends for savella
✉ Email this page to a colleague
Average Pharmacy Cost for savella
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SAVELLA 25 MG TABLET | 00456-1525-60 | 8.17358 | EACH | 2025-01-02 |
| SAVELLA 100 MG TABLET | 00456-1510-60 | 8.16470 | EACH | 2025-01-02 |
| SAVELLA TITRATION PACK | 00456-1500-55 | 8.19090 | EACH | 2025-01-02 |
| SAVELLA 50 MG TABLET | 00456-1550-60 | 8.17752 | EACH | 2025-01-02 |
| SAVELLA 12.5 MG TABLET | 00456-1512-60 | 8.17180 | EACH | 2025-01-02 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Savella Market Analysis and Financial Projection
Market Analysis and Price Projections for Savella
Overview of Savella
Savella, also known as milnacipran, is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used for the treatment of fibromyalgia. It is also indicated for major depressive disorder (MDD) in some regions, although its use for MDD is more limited.
Market Position and Competition
Current Market Status
Savella is one of the key players in the fibromyalgia treatment market, alongside other prominent drugs such as Lyrica (pregabalin) and Cymbalta (duloxetine). The fibromyalgia treatment market has seen significant fluctuations due to factors like generic entries and changing regulatory landscapes.
- As of 2018, the fibromyalgia drug market in major countries like the U.S., France, Germany, Italy, Spain, the UK, and Japan was valued at $1.8 billion, but it declined to $1.4 billion in 2019 due to the generic entry of pregabalin[2].
Regional Market Share
- North America, particularly the U.S., dominates the fibromyalgia treatment market. The U.S. accounts for more than two-thirds of major-market fibromyalgia drug sales. However, market expansion in Europe and Japan is constrained by lower diagnosis rates and less widespread recognition of fibromyalgia[2].
Pricing and Revenue Projections
Annual Costs
- Existing FDA-approved medications like Lyrica, Cymbalta, and Savella typically cost between $5,000 and $8,000 annually per patient. This pricing range is indicative of the premium nature of these treatments[5].
Sales Forecast
- For Savella, sales forecasts vary based on the region and the specific indication. In the U.S., Savella is primarily used for fibromyalgia, while in Japan, it is also approved for major depressive disorder.
- In the U.S., the sales of Savella are influenced by the overall fibromyalgia market trends. Given the competitive landscape, Savella's sales are expected to maintain a stable presence but may face challenges from new entrants and generic versions of other drugs[2][3].
Competitive Landscape
- Savella competes directly with other SNRIs like Cymbalta (duloxetine) and pregabalin (Lyrica). The competition is intense, with each drug vying for market share based on efficacy, safety profile, and pricing.
- Duloxetine, for instance, has been in close competition with pregabalin for market-leading status in the U.S., and Savella also seeks to carve out its niche within this competitive space[2].
Regulatory and Approval Status
Approval and Indications
- Savella is approved for the treatment of fibromyalgia in the U.S. and for major depressive disorder in Japan. However, it has not been granted marketing approval by the European Medicines Agency (EMA) for any indication, although it is available in France for the treatment of MDD[3].
Impact of Regulatory Changes
- Regulatory changes, such as the approval of new treatments or the generic entry of existing drugs, significantly impact the market dynamics. For example, the generic entry of pregabalin led to a sharp decline in the fibromyalgia drug market in 2019[2].
Future Outlook and Growth Potential
Market Growth Projections
- The global fibromyalgia treatment market is projected to grow from $3.07 billion in 2024 to $3.86 billion by 2031, with a compound annual growth rate (CAGR) of 3.3%. This growth is driven by increasing approval and launch of novel fibromyalgia treatments[1].
New Market Opportunities
- Savella could potentially benefit from expanding its indications or entering new markets. However, this would require additional regulatory approvals and a strong marketing strategy to compete with existing and new treatments.
- For instance, if Savella were to be approved for other conditions like chronic pain syndromes or sleep disturbances, it could significantly expand its market share and revenue potential[5].
Key Takeaways
- Market Competition: Savella operates in a highly competitive market dominated by drugs like Lyrica and Cymbalta.
- Pricing: Savella's annual cost per patient ranges between $5,000 and $8,000.
- Regulatory Status: Approved for fibromyalgia in the U.S. and MDD in Japan, but not approved by the EMA.
- Future Growth: The fibromyalgia treatment market is expected to grow, driven by new treatments and increasing diagnosis rates.
FAQs
What is Savella used for?
Savella is primarily used for the treatment of fibromyalgia in the U.S. and major depressive disorder in Japan.
How much does Savella cost annually?
Savella typically costs between $5,000 and $8,000 annually per patient.
What are the main competitors of Savella in the fibromyalgia market?
The main competitors of Savella include Lyrica (pregabalin) and Cymbalta (duloxetine).
Is Savella approved in Europe?
Savella has not been granted marketing approval by the European Medicines Agency (EMA) for any indication, although it is available in France for the treatment of MDD.
What are the growth projections for the fibromyalgia treatment market?
The global fibromyalgia treatment market is projected to grow from $3.07 billion in 2024 to $3.86 billion by 2031, with a CAGR of 3.3%.
Sources
- Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected - Globenewswire
- Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Decline Sharply from $1.8 Billion in 2018 to Only $1.4 Billion in 2019 - FiercePharma
- Research and Markets: Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023 - BusinessWire
- Astellas Pharma Inc. Financial Results for the Q1 of FY2024 - Astellas
- TNXP Revenue Forecast - Moomoo Community
More… ↓
